CBLL
Ceribell, Inc. Health Care Electromedical & Electrotherapeutic Apparatus Russell 3000
$26.58Close
$996.4MMarket cap
$10.92 – $27.8252-week range
Nov 3, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
- Near its high 4% below its 52-week high
Cautions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
down 2.0%
price change
1mo
up 9.0%
price change
12-month return
up 135%
market up 11% ·
its own up 110%
F-score
4 / 9
Weak
Altman Z
13.69
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
6.4×
price / book
Earnings yield
down 6.0%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 36%
year on year
EPS growth
—
latest quarter
Sales growth
up 33%
latest quarter · +3 pts
ROE
down 31%
return on equity
Free cash margin
down 47%
-$41.6M FCF
D/E
0.13
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
Repair signals
- Gross margin 86.7% → 87.9%
Trade setup
ATR%
4.8%
$1.28 a day · 2×ATR $24.02
RS
94 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
1.44
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.6% over the year, from 36m to 37m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+14% vs market2 sessions after results
Financials
- Gross 88%
- Net -60%
- Free cash -47%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $45.2M | $65.4M | $89.1M |
| Gross margin | 84% | 87% | 88% |
| Operating income | -$30.0M | -$39.7M | -$58.4M |
| Net income | -$29.5M | -$40.5M | -$53.4M |
| Net margin | -65% | -62% | -60% |
| Earnings per share | -$5.56 | -$3.39 | -$1.46 |
| Free cash flow | -$30.1M | -$36.4M | -$41.6M |
| Free cash margin | -67% | -56% | -47% |
| Cash | $34.5M | $194.4M | $40.5M |
| Long-term debt | $11.8M | $19.6M | $19.8M |
| Shareholders' equity | -$112.3M | $191.2M | $155.3M |
| Shares outstanding | 5.43m | 35.85m | 37.49m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 10, 2026 | Results ↗ |
| Jul 30, 2026 | Director or officer change ↗ |
| Jun 2, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Results ↗ |
| Feb 24, 2026 | Results ↗ |
| Jan 5, 2026 | Other events ↗ |
| Jan 2, 2026 | Director or officer change ↗ |
| Dec 12, 2025 | Material agreement ↗ |
| Dec 9, 2025 | Other events ↗ |
| Nov 24, 2025 | Other events ↗ |
| Nov 4, 2025 | Results ↗ |
| Sep 24, 2025 | Material agreement ↗ |